Rapport Therapeutics (RAPP) Institutional Ownership $15.60 +0.06 (+0.39%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$15.60 0.00 (0.00%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Rapport Therapeutics (NASDAQ:RAPP)Number ofInstitutional Buyers(last 12 months)51TotalInstitutional Inflows(last 12 months)$175.73MNumber ofInstitutional Sellers(last 12 months)10TotalInstitutional Outflows(last 12 months)$3.93M Get RAPP Insider Trade Alerts Want to know when executives and insiders are buying or selling Rapport Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RAPP Institutional Buying and Selling by Quarter Rapport Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/13/2025Affinity Asset Advisors LLC199,643$2.27M0.3%N/A0.547% 8/13/2025Kennedy Capital Management LLC11,230$128K0.0%N/A0.031% 8/12/2025 Rhumbline Advisers24,949$284K0.0%+73.8%0.068% 8/8/2025 Intech Investment Management LLC11,462$130K0.0%N/A0.031% 8/8/2025 Creative Planning10,602$121K0.0%N/A0.029% 8/8/2025 Geode Capital Management LLC333,159$3.79M0.0%+5.5%0.913% 7/28/2025 TD Asset Management Inc196,870$2.24M0.0%+20.9%0.539% 5/29/2025 Rhumbline Advisers14,358$144K0.0%+40.1%0.039% 5/23/2025Siren L.L.C.378,469$3.80M0.2%-1.5%1.037% 5/19/2025UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC203,242$2.04M0.0%N/A0.557% Get the Latest News and Ratings for RAPP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/16/2025Goldman Sachs Group Inc.1,244,310$12.48M0.0%-0.6%3.409% 5/16/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.9,887$99K0.0%+86.4%0.027% 5/15/2025Siren L.L.C.378,469$3.80M0.2%-1.5%1.037% 5/14/2025 Corebridge Financial Inc.8,271$83K0.0%+79.1%0.023% 5/14/2025MetLife Investment Management LLC10,863$109K0.0%+90.2%0.030% 5/14/2025Jump Financial LLC13,760$138K0.0%N/A0.038% 5/14/2025T. Rowe Price Investment Management Inc.1,551,925$15.57M0.0%-5.2%4.252% 5/12/2025 Nuveen LLC21,873$219K0.0%N/A0.060% 5/12/2025 Swiss National Bank31,900$320K0.0%+77.2%0.087% 5/9/2025 Deutsche Bank AG6,502$65K0.0%+180.6%0.018% 5/9/2025 Charles Schwab Investment Management Inc.90,968$912K0.0%+23.8%0.249% 5/8/2025 XTX Topco Ltd15,442$155K0.0%N/A0.042% 5/7/2025 TD Asset Management Inc162,818$1.63M0.0%-8.5%0.446% 4/30/2025 Alps Advisors Inc.26,128$262K0.0%-11.7%0.072% 4/29/2025 Bank of New York Mellon Corp35,482$356K0.0%+77.7%0.097% 4/8/2025 Rhumbline Advisers14,358$144K0.0%+40.1%0.039% 4/8/2025 Catalyst Private Wealth LLC10,000$100K0.0%N/A0.027% 4/7/2025 GAMMA Investing LLC9,208$918K0.0%+91,980.0%0.025% 3/18/2025California State Teachers Retirement System8,571$152K0.0%+1,151.2%0.023% 2/17/2025Woodline Partners LP181,530$3.22M0.0%-2.7%0.496% 2/17/2025 Deutsche Bank AG2,317$41K0.0%N/A0.006% 2/17/2025Crestline Management LP27,496$488K0.0%N/A0.075% 2/17/2025Bank of America Corp DE6,578$117K0.0%-65.6%0.018% 2/17/2025Acuta Capital Partners LLC16,400$291K0.3%-6.8%0.045% 2/14/2025Virtus ETF Advisers LLC3,740$66K0.0%N/A0.010% 2/14/2025T. Rowe Price Investment Management Inc.1,636,931$29.04M0.0%-5.2%4.475% 2/14/2025Price T Rowe Associates Inc. MD1,143,384$20.29M0.0%+9.2%3.126% 2/14/2025 TRV GP V LLC7,135,233$126.58M43.1%N/A19.506% 2/14/2025 TRV GP VI LLC969,218$17.19M14.7%N/A2.650% 2/13/2025Barclays PLC18,497$328K0.0%+43.8%0.051% Altucher: It Looks Like My Trump prediction is coming true (Ad)New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.See Altucher’s Trump crypto prediction here2/13/2025 Legal & General Group Plc9,523$169K0.0%+947.6%0.026% 2/13/2025Wells Fargo & Company MN4,824$86K0.0%+38.9%0.013% 2/12/2025 Geode Capital Management LLC210,676$3.74M0.0%+4.4%0.576% 2/12/2025Alliancebernstein L.P.1,098,415$19.49M0.0%+0.9%3.003% 2/12/2025Norges Bank48,452$860K0.0%N/A0.132% 2/12/2025 JPMorgan Chase & Co.7,170$127K0.0%+77.8%0.020% 2/11/2025 KLP Kapitalforvaltning AS1,900$34K0.0%N/A0.005% 2/10/2025 Swiss National Bank18,000$319K0.0%N/A0.049% 1/31/2025New York State Common Retirement Fund3,500$62K0.0%N/A0.010% 1/30/2025 Rhumbline Advisers10,249$182K0.0%-35.3%0.028% 1/24/2025 Jennison Associates LLC62,287$1.11M0.0%N/A0.170% 1/24/2025China Universal Asset Management Co. Ltd.7,756$138K0.0%N/A0.021% 12/26/2024 JPMorgan Chase & Co.4,033$83K0.0%N/A0.011% 11/19/2024Barclays PLC12,863$264K0.0%+36.8%0.035% 11/16/2024 Geode Capital Management LLC201,748$4.13M0.0%N/A0.552% 11/15/2024Barclays PLC12,863$264K0.0%+36.8%0.035% 11/15/2024State Street Corp58,046$1.19M0.0%N/A0.159% 11/15/2024Maven Securities LTD29,930$613K0.0%N/A0.082% 11/14/2024Eventide Asset Management LLC110,401$2.26M0.0%+120.8%0.302% 11/14/2024Acuta Capital Partners LLC17,600$360K0.3%-12.0%0.048% 11/14/2024MetLife Investment Management LLC5,710$117K0.0%N/A0.016% 11/13/2024BNP Paribas Financial Markets1,684$34K0.0%N/A0.005% 11/13/2024FMR LLC5,486,468$112.36M0.0%+10.1%14.999% 11/13/2024The Manufacturers Life Insurance Company77,344$1.58M0.0%+2.4%0.211% 11/12/2024 Charles Schwab Investment Management Inc.73,146$1.50M0.0%N/A0.200% 11/7/2024LMR Partners LLP20,000$410K0.0%-60.0%0.055% 10/23/2024 Values First Advisors Inc.1,507$31K0.0%N/A0.004% 10/3/2024 SG Americas Securities LLC4,934$101K0.0%N/A0.014% 8/27/2024Logos Global Management LP208,910$4.86M0.4%N/A0.591% 8/16/2024Perceptive Advisors LLC748,183$17.40M0.4%N/A2.045% 8/15/2024The Manufacturers Life Insurance Company75,516$1.76M0.0%N/A0.206% 8/15/2024Millennium Management LLC116,782$2.72M0.0%N/A0.319% 8/14/2024Squarepoint Ops LLC16,345$380K0.0%N/A0.045% 8/14/2024Sandia Investment Management LP5,000$116K0.2%N/A0.014% 8/14/2024ARCH Venture Management LLC3,728,738$86.73M31.6%N/A10.193% 8/14/2024Davidson Kempner Capital Management LP10,000$229K0.0%N/A0.027% 8/10/2024Sofinnova Investments Inc.1,951,562$45.39M2.4%N/A5.516% 8/9/2024 Johnson & Johnson2,498,051$58.11M14.5%N/A7.061% 8/3/2024 TD Asset Management Inc101,522$2.36M0.0%N/A0.287% (Data available from 1/1/2016 forward) RAPP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RAPP shares? During the previous two years, 61 institutional investors and hedge funds held shares of Rapport Therapeutics. The most heavily invested institutionals were TRV GP V LLC ($126.58M), FMR LLC ($112.36M), ARCH Venture Management LLC ($86.73M), Johnson & Johnson ($58.11M), Sofinnova Investments Inc. ($45.39M), Price T Rowe Associates Inc. MD ($20.29M), and Alliancebernstein L.P. ($19.49M).Learn more on Rapport Therapeutics' institutional investors. Which institutional investors have been buying Rapport Therapeutics' stock? Of the 53 institutional investors that purchased Rapport Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: TRV GP V LLC ($7.14M), ARCH Venture Management LLC ($3.73M), Johnson & Johnson ($2.50M), Sofinnova Investments Inc. ($1.95M), TRV GP VI LLC ($969.22K), Perceptive Advisors LLC ($748.18K), and FMR LLC ($503.12K). How much institutional buying is happening at Rapport Therapeutics? Institutional investors have bought a total of 11,164,576 shares in the last 24 months. This purchase volume represents approximately $175.73M in transactions. Which of Rapport Therapeutics' major shareholders have been selling company stock? Of the 10 institutional investors that sold Rapport Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: T. Rowe Price Investment Management Inc. ($175.19K), LMR Partners LLP ($30K), TD Asset Management Inc ($15.09K), Bank of America Corp DE ($12.53K), Siren L.L.C. ($11.46K), Goldman Sachs Group Inc. ($7.83K), and Rhumbline Advisers ($5.59K). How much institutional selling is happening at Rapport Therapeutics? Institutional investors have sold a total of 269,764 shares in the last 24 months. This volume of shares sold represents approximately $3.93M in transactions. Related Companies AGIO Institutional Ownership DNLI Institutional Ownership IDYA Institutional Ownership TARS Institutional Ownership IRON Institutional Ownership HRMY Institutional Ownership MESO Institutional Ownership CGON Institutional Ownership ADPT Institutional Ownership VCEL Institutional Ownership This page (NASDAQ:RAPP) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.